Related references
Note: Only part of the references are listed.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
Stefan Schreiber et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Anti-Tumor Necrosis Factor Therapy in Crohn's Disease: More Information and More Questions About the Long Term
Charles N. Bernstein
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
Filip Baert et al.
GASTROENTEROLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mucosal Healing Predicts Long-term Outcome of Maintenance Therapy with Infliximab in Crohn's Disease
Fabian Schnitzler et al.
INFLAMMATORY BOWEL DISEASES (2009)
Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease
R. Panaccione et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort
Kathrine Frey Froslie et al.
GASTROENTEROLOGY (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
Paul Rutgeerts et al.
GUT (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
P Rutgeerts et al.
GASTROINTESTINAL ENDOSCOPY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease
Michael R. Konikoff et al.
INFLAMMATORY BOWEL DISEASES (2006)
Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries
GR Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Long-term evolution of disease behavior of Crohn's disease
J Cosnes et al.
INFLAMMATORY BOWEL DISEASES (2002)
Share Paper
